Cargando…
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
Autores principales: | Andres-Ejarque, Rosa, Ale, Hira Bahadur, Grys, Katarzyna, Tosi, Isabella, Solanky, Shane, Ainali, Chrysanthi, Catak, Zeynep, Sreeneebus, Hemawtee, Saklatvala, Jake, Dand, Nick, de Rinaldis, Emanuele, Chapman, Anna, Nestle, Frank O., Barnes, Michael R., Warren, Richard B., Reynolds, Nick J., Griffiths, Christopher E. M., Barker, Jonathan N., Smith, Catherine H., Di Meglio, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677717/ https://www.ncbi.nlm.nih.gov/pubmed/34916493 http://dx.doi.org/10.1038/s41467-021-27447-6 |
Ejemplares similares
-
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
por: Andres-Ejarque, Rosa, et al.
Publicado: (2021) -
Characterization of innate lymphoid cells (ILC) in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis
por: Villanova, Federica, et al.
Publicado: (2013) -
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
por: Tsakok, Teresa, et al.
Publicado: (2023) -
Genetic Validation of Psoriasis Phenotyping in UK Biobank Supports the Utility of Self-Reported Data and Composite Definitions for Large Genetic and Epidemiological Studies
por: Saklatvala, Jake R., et al.
Publicado: (2023) -
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
por: Wilkinson, Nina, et al.
Publicado: (2019)